Post-Surgical Opdivo ‘Just Makes Sense’ for Stage 2B, 2C Melanoma
Source: CureToday, November 2023
An expert reflects on the recent FDA approval of adjuvant Opdivo for patients with stage 2B or 2C melanoma.
Even after patients with stage 2B or 2C melanoma have their disease surgically removed, there is still a chance that it can come back, highlighting the need for post-surgical — also known as “adjuvant” — therapies. With that, the Food and Drug Administration (FDA) approved adjuvant Opdivo (nivolumab) for this patient population.
“There’s always a risk, with every cancer, that it can migrate into the tiny blood or lymph vessels and make its way outside of where the surgery was,” Dr. Craig Devoe, associate professor of Medicine at the R.J. Zuckerburg Cancer Center, said in an interview with CURE®. “So, we give preventative therapy, adjuvant therapy, to mitigate that risk.”